Canadian CLL Meeting 2015 Anti-Malarial Drugs Disrupt Lysosomes in Chronic Lymphocytic Leukemia (CLL) Cells

نویسندگان

  • Rebecca Dielschneider
  • Hannah Eisenstat
  • Wenguang He
  • James Johnston
  • Spencer Gibson
  • Cheryl P. Peltier
  • Rebecca Lang
  • Wayne Hicks
  • Armando Poeppl
  • Versha Banerji
چکیده

CLL is the most common type of leukemia in the Western world and represents the most common cause of secondary immunodeficiency which can benefit from immunoglobulin replacement therapy (IgRT). While immunoglobulin replacement therapy is usually administered intravenously in a hospital or outpatient facility, the availability of subcutaneous (SCIg) administration is often very appreciated by patients, for it offers greater flexibility and can lead to improved independence and quality of life. We conducted a pilot study to assess the feasibility of subcutaneous immunoglobulin replacement (SCIG) in patients with secondary hypogammaglobulinemia due to B lymphocytederived malignancies. Five patients were transitioned from intravenous replacement (IVIG) to SCIG. Mean patients’ serum levels of IgG on IVIg were 7.32 g/L while they increased to 11.39 g/L on SCIg. For IVIg, infections occurred almost once a month on average, while they were almost reduced to none after the SCIg switch. Moreover, no adverse effects were manifest after the SCIg change, as opposed to some serious discomfort in the case of 2 patients under the IVIg regime. This, in turn, contributed to an important reduction in the number of hospital visits related to the treatment. This pilot trial suggests that SCIG may represent a feasible alternative to IVIG for the management of patients with secondary hypogammagloublinemia A Canadian Perspective on the Use of Immunoglobulin Therapy to Reduce Infectious Complications in Chronic Lymphocytic Leukemia S. Lachance MD,* A. Christofides MSc,† J. Lee MD,‡ L. Sehn MD,§ B. Ritchie MD,|| C. Shustik MD,# D. Stewart MD,** C. Toze MD,§ E. Haddad MD,†† D. C. Vinh MD#, Ayman

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Effect of curcumin on growth inhibition and gene expression reduction in chronic lymphocytic leukemia cells (CLL-CII)

Introduction: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in adults living in Western countries. with a diverse clinical course that due to life expectancy less than two years between patients finding ,new therapeutic strategies is essential for it. Curcumin as the biologic active of turmeric, has many biological properties such as anti-inflammatory, anti-oxidant, anti-diab...

متن کامل

Analysis of HLA-G Gene Expression in B-Lymphocytes from Chronic Lymphocytic Leukemia Patients

The human leukocyte antigen G (HLA-G) molecule exhibits limited tissue distribution, low polymorphism and alternative splicings that generate seven HLA-G isoforms. HLA-G exerts multiple immunoregulatory functions. Recent studies indicate an ectopic up-regulation in tumor cells that may favor their escape from anti-tumor immune responses. This study it is an effort to clarify the presence of HLA...

متن کامل

Chronic lymphocytic leukemia, biology, new diagnosis and treatment: review article

Chronic lymphocytic leukemia (CLL) is a malignancy of B CD5+cells and is the most common type of leukemia in adults. The disease is more common in men over 50 years in western countries. CLL is associated with defective apoptosis in B cells. CLL was traditionally regarded as a disease that occurs before naïve B cells meet the antigen in the lymph nodes. Laboratory diagnosis requires white blood...

متن کامل

Expression Profiles of miR-93 and miR-330 in Iranian Patients with Chronic Lymphocytic Leukemia

Background and Aims: Chronic lymphocytic leukemia (CLL) is the most common adult human leukemia. MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression. Research has shown that in CLL, microRNAs can have function as oncogenes or tumor suppressors. Some studies demonstrated that the expression of microRNA-93 (miR-93) and microRNA-330 (miR-330) have been changed in several can...

متن کامل

GPI-Anchored Fibromodulin as a Novel Target in Chronic Lymphocytic Leukemia: Diagnostic and Therapeutic Implications

Background: We have previously reported the aberrant expression of Fibromodulin (FMOD) in patients with chronic lymphocytic leukemia (CLL). Although FMOD has been considered as a cytoplasmic or secretory protein, we discovered the cell surface expression of FMOD in leukemic B cells via anchoring with glycosylphosphatidylinositol (GPI). Objective: To evaluate FM...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

برای دانلود متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

ثبت نام

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

عنوان ژورنال:

دوره   شماره 

صفحات  -

تاریخ انتشار 2015